• High Extracellular Viscosity Drives Chemoresistance via P-gp

  2026-06-10

  This study reveals that high extracellular fluid viscosity in the tumor microenvironment promotes chemoresistance by upregulating P-glycoprotein (P-gp) through mechanosensitive signaling pathways. These findings suggest that targeting tumor viscosity could offer new strategies for overcoming drug resistance in cancer therapy.

• Belinostat (PXD101): Reliable HDAC Inhibition for Cancer Ass

  2026-06-10

  This scenario-driven guide addresses common laboratory challenges in cell viability and proliferation assays, highlighting the scientific advantages of Belinostat (PXD101), SKU A4096. Emphasizing workflow reproducibility and quantitative rigor, it demonstrates how APExBIO’s formulation enables consistent results in epigenetic cancer therapy research.

• Trichostatin A (TSA): Workflow-Driven Advances in Cancer Epi

  2026-06-09

  Trichostatin A (TSA) empowers researchers to interrogate epigenetic regulation in cancer, offering robust inhibition of HDAC enzymes for enhanced cell-based assay sensitivity. This article delivers workflow-anchored guidance, troubleshooting strategies, and new insights from ferroptosis studies—positioning APExBIO TSA as a benchmark for experimental precision.

• Systematic Profiling of AKT Inhibitor Classes Reveals Distin

  2026-06-09

  This study systematically compares ATP-competitive and allosteric AKT inhibitors, revealing unique biochemical signatures, isoform-specific resistance, and implications for therapeutic combinations. The findings clarify the functional diversity among AKT inhibitors and inform the rational design of targeted cancer therapy workflows.

• TBXA2R Drives ERM Activation and Metastasis in TNBC Cells

  2026-06-08

  The reference study uncovers how the thromboxane A2 receptor (TBXA2R), a GPCR, activates the ERM protein family to promote motility, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. By elucidating a novel TBXA2R–ERM signaling axis, it highlights therapeutic targets for combating metastatic progression and advances mechanistic understanding of GPCR-mediated cytoskeletal regulation.

• Filipin III: Advanced Cholesterol Detection in Membrane Rese

  2026-06-08

  Filipin III, a polyene macrolide antibiotic from APExBIO, sets the standard for high-resolution, reproducible cholesterol detection in biological membranes. Its unique fluorescence-quenching mechanism enables precise mapping of cholesterol-rich microdomains, empowering workflows from pulmonary fibrosis modeling to metabolic disease and immunology.

• Pravastatin Sodium: Optimizing HMG-CoA Reductase Inhibitor W

  2026-06-07

  Pravastatin sodium stands out as a highly selective HMG-CoA reductase inhibitor, enabling precise cholesterol biosynthesis inhibition in both cell-based and animal models. This guide distills applied workflows, troubleshooting, and translational insights to maximize reproducibility and clarity in cardiovascular and exploratory oncology research.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-06-06

  The referenced study identifies moesin (MSN) as a novel and quantifiable biomarker of endothelial injury severity in sepsis, linking its expression to vascular permeability and organ dysfunction. By delineating the molecular mechanisms of MSN-mediated endothelial barrier disruption, this work provides a foundation for improved diagnosis and targeted research in sepsis pathophysiology.

• Veratridine: Voltage-Gated Sodium Channel Opener in Research

  2026-06-05

  Veratridine’s unique action as a voltage-gated sodium channel opener empowers high-sensitivity sodium channel dynamics and excitotoxicity studies. Unlock superior assay reproducibility, functional phenotyping, and UBXN2A-mediated cancer research with APExBIO’s rigorously validated Veratridine.

• Rosiglitazone (SKU A4304): Reliable PPARγ Agonist for Metabo

  2026-06-05

  This scenario-driven guide addresses common laboratory challenges in cell viability, adipogenesis, and insulin sensitivity assays, highlighting how Rosiglitazone (SKU A4304) provides robust, reproducible solutions. Drawing on recent functional genomics data and validated protocols, the article empowers researchers to optimize experimental design, data interpretation, and vendor selection in metabolic and type II diabetes research.

• Dibutyryl-cAMP, Sodium Salt: Decidualization, Metabolism, an

  2026-06-04

  Explore the cutting-edge use of Dibutyryl-cAMP, sodium salt in metabolic and reproductive biology. This article uniquely connects cAMP analog signaling to endometrial decidualization and lipid metabolism, offering novel assay guidance for advanced researchers.

• Multiomics Insights into Bifendate Mechanisms in Acute Liver

  2026-06-04

  This study employs a multiomics approach to dissect the molecular actions of bifendate (DDB) in acute liver injury, revealing how it modulates gene and protein networks linked to immune and metabolic pathways. Findings clarify bifendate’s regulation of specific ncRNAs and immune/inflammation proteins, offering new mechanistic perspectives for targeted hepatoprotection.

• HDAC Inhibitors as NUT Carcinoma Repressors: Insights from C

  2026-06-03

  Shiota et al. conducted a high-throughput chemical screen and identified diverse histone deacetylase (HDAC) inhibitors as effective repressors of NUT function in NUT carcinoma. Their findings clarify the mechanistic link between chromatin acetylation, megadomain formation, and oncogenic gene expression, highlighting HDAC inhibition as a promising therapeutic strategy for this aggressive cancer.

• Silybin A: Applied Protocols for Liver Disease and Cancer Re

  2026-06-03

  Silybin A, the bioactive cornerstone of Silymarin, is revolutionizing hepatoprotective and cancer biology assays by enabling targeted pathway interrogation and robust antioxidant modeling. This guide decodes actionable experimental workflows, nuanced troubleshooting, and the translational edge Silybin A brings to liver disease and metastasis research.

• S Tag Peptide: Technical Guide for Fusion Tag Applications

  2026-06-02

  S Tag Peptide (SKU A6007) is a short, highly soluble fusion tag designed to enhance recombinant protein detection and purification, particularly when standard solubility tags are ineffective. It is best suited to workflows with validated anti-S-Tag antibody systems and where ethanol solubility is not required. Avoid using it in workflows lacking compatible detection reagents or demanding long-term peptide solution storage.

15586 records 1/1040 page Next 12345 下5页 Last page